Table 2.

Toxicity by treatment group

		Attribution of AE to Study Medication						Total
		Possible		Unlikely*		Unrelated**
		Minocycline	Placebo	Minocycline	Placebo	Minocycline	Placebo
CTCAE grade, N1	1	0	0	1	2	1	5	9
	2	0	0	13	9	3	4	29
	3	0	0	3	2	2	5	12
	4	0	0	0	0	0	0	0
Total, N		0	0	17	13	6	14	50

¹Number of events

^*Grade 1 unlikely AEs include dermatitis, fever and weight loss.

^*Grade 2 unlikely AEs include anorexia, dehydration, diarrhea, dysgeusia, dysphagia, dyspnea, erythema, esophagitis, esophagtis, fatigue, fever, and odynophagia

^*Grade 3 unlikely AEs include cough, dehydration, dermatitis, dysphagia, and dyspnea.

^**Grade 1 unrelated AEs include alopecia, dermatitis, erythema, high bilirubin, and odynophagia.

^**Grade 2 unrelated AEs include AST increased, diarrhea, esophagitis, fatigue, odynophagia, rectal bleeding, and vomiting.

^**Grade 3 unrelated AEs include dehydration, dysphagia, dyspnea, nausea, pain in extremity, and pulmonary embolism

CTCAE, Common Terminology Criteria for Adverse Events version 3